PTCT PTC Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$81.33 -4.1%
$674.6M mkt cap
executive summary
PTC Therapeutics, Inc. (PTCT) is a $674.6M company. Revenue is $1.73B (+114.5% y/y) at a 39% net margin. It is profitable. Our health score is C (61/100). 2 red flags on file. Held by 1 tracked funds. It funds itself; low dilution risk.
Revenue (FY)
$1.73B
+114.5% y/y
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (0.82).
⚠One-sided insider selling
16 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 16
Cash & ST investments
$1.89B
Operating cash flow
$711.2M
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.